Fineline Cube

Follow:
14475 Articles
GluBio Pharmaceutical Advances GLB-002 Molecular Glue Degrader to Phase II for Relapsed Follicular Lymphoma
CompanyDrug

GluBio Pharmaceutical Advances GLB-002 Molecular Glue Degrader to Phase II for Relapsed Follicular Lymphoma

CompanyDrug

Henlius Biotech Secures European Commission Approval for Poherdy Biosimilar to Roche’s Perjeta

AbbVie Submits FDA Application for RINVOQ in Severe Alopecia Areata – Expanding JAK Inhibitor Franchise
CompanyDrug

AbbVie Submits FDA Application for RINVOQ in Severe Alopecia Areata – Expanding JAK Inhibitor Franchise

Medtronic Secures CE Mark for Stealth AXiS Surgical System – Next-Generation Integrated Robotics Platform
CompanyMedical Device

Medtronic Secures CE Mark for Stealth AXiS Surgical System – Next-Generation Integrated Robotics Platform

Pfizer Extends VYNDAMAX Patent Protection to 2031 Through Generic Settlements
CompanyDrug

Pfizer Extends VYNDAMAX Patent Protection to 2031 Through Generic Settlements

CompanyDrug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Johnson & Johnson's Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise
CompanyDrug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn's Disease – Expanding IL-23 Inhibitor Franchise
CompanyDrug

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise

CompanyDrug

GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development

CompanyDrug

Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline

CompanyDrug

Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors – Novel Bispecific Fc Fusion Protein Targets “Cold Tumors”

Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication
Others

Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication